September 20th, 2012
Is skepticism of industry-funded trials warranted even when they are designed, conducted, and reported with the utmost rigor?
March 27th, 2012
Light, not just heat, is generated in a highly animated and entertaining session on how to interpret research data.
January 26th, 2012
A pharmaceutical sales rep comes to your office bringing lunch. He shows you a graphic stating that Multaq (dronedarone) reduced the primary endpoint in the ATHENA trial by 24%. The fine print shows an impressive P value: <0.0001. You come away satisfied that this drug looks good. You may not realize it, but you also […]